ism2 Antibody

What is ISM2 protein and why is it important for research?

ISM2 (isthmin 2 homolog) is a protein containing a type 1 thrombospondin domain, which is present in thrombospondin and various proteins involved in the complement pathway and extracellular matrix. In humans, ISM2 expression is almost exclusively specific to the placenta, making it an important target for reproductive and developmental research . The protein has a molecular weight of approximately 64 kDa and is also known by alternative designations including TAIL1 and THSD3 . Recent studies have implicated ISM2 in pregnancy complications and cancer development, suggesting it may have angiogenic functions, which highlights its importance as a research subject .

What are the primary applications for ISM2 antibodies in research?

ISM2 antibodies are primarily used in several key laboratory techniques:

• Western Blot (WB): For detecting and quantifying ISM2 protein expression in cell or tissue lysates, typically using dilutions of 1:500-1:1000 .

• Immunohistochemistry (IHC): For visualizing ISM2 protein distribution in tissue sections, with recommended dilutions between 1:20-1:200 .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of ISM2 levels in serum or other biological fluids .

• Immunofluorescence (IF)/Immunocytochemistry (ICC): For cellular localization studies at dilutions of 1:20-1:200 .

These applications enable researchers to investigate ISM2 expression patterns, tissue distribution, and potential functions in various physiological and pathological contexts.

What sample types have been successfully tested with ISM2 antibodies?

ISM2 antibodies have demonstrated reactivity with several sample types:

When working with new sample types, optimization of antibody concentration and experimental conditions is recommended for optimal results .

What are the recommended storage conditions for ISM2 antibodies?

For maximum stability and activity retention, ISM2 antibodies should be stored at -20°C . Most commercial preparations are supplied in storage buffers containing stabilizers such as glycerol (typically 50%) and preservatives like Proclin300 (0.03%), with pH adjusted to approximately 7.3-7.4 . To prevent repeated freeze-thaw cycles that can degrade antibody quality, it is advisable to aliquot the antibody solution before freezing . Under these storage conditions, antibodies generally maintain their activity for approximately one year .

How should researchers optimize ISM2 antibody protocols for immunohistochemistry?

Optimization of ISM2 antibody protocols for immunohistochemistry requires careful consideration of several parameters:

• Antigen Retrieval: Evidence suggests that antigen retrieval with TE buffer at pH 9.0 is effective for ISM2 detection, although citrate buffer at pH 6.0 may serve as an alternative . The choice between these methods should be experimentally determined based on your specific tissue sample.

• Protocol Details: For optimal results, tissue sections should be deparaffinized in xylene and rehydrated through graded alcohols. After quenching endogenous peroxidase activity with 1% H₂O₂ in PBS for approximately 10 minutes, non-specific binding can be reduced by incubating sections with 5% non-fat milk in PBS for 30 minutes .

• Visualization Systems: Polymer-based visualization systems with diaminobenzidine as the chromogen have been successfully employed for ISM2 detection, followed by hematoxylin counterstaining .

• Controls: Include both positive controls (placental tissue is recommended) and negative controls (primary antibody replaced with isotype-matched IgG) to validate staining specificity .

• Scoring System: For cancer or pathology research, develop a consistent scoring system for staining intensity (e.g., 0, 1+, 2+, 3+) and document the percentage of immunoreactive cells to enable quantitative analysis .

What are the critical considerations when using ISM2 antibodies for Western blot analysis?

When employing ISM2 antibodies for Western blot analysis, researchers should address several critical factors:

How can researchers effectively measure ISM2 expression in preeclampsia studies?

Research on ISM2 in preeclampsia requires specialized approaches to ensure reliable results:

• Study Design: Implement a prospective, cross-sectional design with clearly defined patient groups (preeclampsia, gestational hypertension, and normotensive pregnancy controls) matched for relevant demographic and clinical variables .

• Sample Collection: For serum analysis, standardize the timing of blood collection relative to disease onset and gestational age. Process samples consistently to minimize pre-analytical variability .

• Quantification Method: Employ quantitative sandwich ELISA techniques with purified human ISM2 antibodies. Commercial kits have been validated for this purpose, with appropriate sensitivity and specificity characteristics .

• Complementary Approaches: Combine serum measurements with placental tissue analysis using immunohistochemistry to correlate circulating levels with tissue expression patterns .

• Statistical Analysis: When comparing ISM2 levels between patient groups, apply appropriate statistical tests based on data distribution. Previous research has identified statistically significant decreases in ISM2 levels in preeclampsia patients (p = 0.036), which can serve as a reference point .

What are the key considerations for troubleshooting weak or non-specific ISM2 antibody signals?

When encountering signal issues with ISM2 antibodies, consider the following troubleshooting approaches:

• Antibody Selection: Different antibody clones may perform differently depending on the application. Monoclonal antibodies offer higher specificity but may recognize only specific epitopes, while polyclonal antibodies provide stronger signals but potentially increased background .

• Epitope Accessibility: ISM2 contains a thrombospondin domain and may interact with extracellular matrix components, potentially masking epitopes. More stringent antigen retrieval methods may be required .

• Cross-Reactivity Assessment: When testing in non-human samples, verify species cross-reactivity. While some ISM2 antibodies react with both human and mouse samples, reactivity with other species should be experimentally confirmed .

• Signal Amplification: For low-abundance detection, consider signal amplification methods such as tyramide signal amplification for immunohistochemistry or more sensitive chemiluminescent substrates for Western blot.

• Blocking Optimization: If background is problematic, experiment with different blocking agents (BSA, normal serum, commercial blockers) to identify the optimal formulation for your specific application.

How is ISM2 antibody being used to investigate cancer biology?

ISM2 antibody applications in cancer research have revealed several important findings:

• Expression Profile: Immunohistochemical studies have demonstrated that ISM2 is overexpressed in choriocarcinoma compared to normal tissues, suggesting potential roles in cancer progression .

• Comparative Oncology: When investigating ISM2 expression across different cancer types, researchers have employed standardized immunohistochemistry protocols with consistent scoring systems to enable meaningful comparisons. This approach has allowed for the examination of ISM2 expression in lung, prostate, colon, gastric and breast cancers in comparison to choriocarcinoma .

• Angiogenesis Connection: The observed overexpression of ISM2 in choriocarcinoma, combined with its decreased levels in preeclampsia (a condition characterized by defective placental angiogenesis), suggests that ISM2 may function as an angiogenic factor. This hypothesis provides a rational basis for further investigation of ISM2 as a potential therapeutic target in cancer biology .

• Methodological Approach: For cancer studies, a multi-modal approach combining tissue immunohistochemistry with serum protein quantification provides the most comprehensive assessment of ISM2's role in cancer development and progression.

What considerations are important when analyzing ISM2 expression data in reproductive disorders?

When analyzing ISM2 expression in reproductive disorders, researchers should consider several methodological aspects:

• Control Selection: Proper selection of control groups is crucial. For preeclampsia studies, both normotensive pregnant women and those with gestational hypertension without proteinuria serve as important comparison groups to distinguish ISM2 changes specific to preeclampsia from those related to hypertension alone .

• Gestational Age Matching: Since protein expression can vary throughout pregnancy, matching cases and controls for gestational age is essential for valid comparisons .

• Statistical Analysis: For immunohistochemical data, non-parametric tests are often more appropriate due to the ordinal nature of staining intensity scores. For serum concentration data, determine whether parametric assumptions are met before choosing statistical tests .

• Data Interpretation: When analyzing paired tissue and serum samples, correlation analyses can provide insights into the relationship between local tissue expression and circulating levels of ISM2. This approach helps determine whether serum ISM2 primarily reflects placental production or has contributions from other tissues .

• Multiple Testing Correction: When comparing ISM2 levels across multiple patient groups or correlating with various clinical parameters, apply appropriate corrections for multiple testing to avoid false-positive results .

How should researchers validate the specificity of ISM2 antibodies?

Comprehensive validation of ISM2 antibody specificity is essential for reliable research results:

• Positive Controls: Include known ISM2-expressing tissues such as human placenta or cells like L02 in your validation protocol .

• Negative Controls: Employ methodology-specific negative controls:

  • For Western blot: Include ISM2-knockdown or knockout samples if available

  • For immunohistochemistry: Replace primary antibody with isotype-matched IgG from the same species

  • For ELISA: Include blank wells and standard curves to establish detection limits

• Preabsorption Tests: Perform preabsorption of the antibody with the immunizing peptide to confirm binding specificity. Signal elimination upon preabsorption supports antibody specificity .

• Multiple Antibody Comparison: When possible, compare results obtained with different antibodies targeting distinct epitopes of ISM2 to confirm consistent detection patterns.

• Correlation With mRNA Expression: Correlate protein detection with ISM2 mRNA expression using techniques such as RT-PCR or RNA-seq in the same samples to provide additional validation.

What are the optimal conditions for detecting ISM2 in serum samples using ELISA?

For optimal ELISA-based detection of ISM2 in serum, researchers should consider:

• Kit Selection: Commercial sandwich ELISA kits specifically developed for human ISM2 quantification have been validated for serum analysis. These kits typically employ purified human ISM2 antibodies for capture and detection .

• Sample Processing: Standardize sample collection and processing protocols. Serum should be separated promptly after blood collection and stored at -80°C until analysis to preserve protein integrity .

• Assay Performance Characteristics: Consider the sensitivity and dynamic range of the assay. Published research indicates that commercial kits have adequate sensitivity for detecting ISM2 in serum samples from both healthy individuals and patients with conditions like preeclampsia .

• Quality Control: Include internal quality controls in each assay run. Some studies have measured related proteins like ISM1 as internal controls to validate the assay methodology .

• Dilution Protocol: Determine the optimal sample dilution through preliminary experiments. Serum samples may require dilution to bring ISM2 concentrations within the linear range of the standard curve.

How can researchers effectively analyze and interpret immunohistochemical data for ISM2?

For rigorous analysis of immunohistochemical data for ISM2, researchers should:

• Standardized Scoring System: Implement a consistent scoring system that captures both staining intensity (0, 1+, 2+, 3+) and the percentage of positive cells. This approach allows for semi-quantitative analysis and meaningful comparisons across different samples and studies .

• Blinded Assessment: Have pathologists or trained observers evaluate staining patterns without knowledge of sample identity or clinical information to minimize bias.

• Cellular and Subcellular Localization: Document not only the presence of ISM2 staining but also its cellular and subcellular distribution patterns, which may provide insights into protein function and processing.

• Comparative Analysis: When comparing ISM2 expression across different tissue types or disease states, analyze multiple samples from each category to account for biological variability.

• Statistical Approaches: For comparing staining intensity between groups, non-parametric tests like Mann-Whitney U or Kruskal-Wallis may be more appropriate than parametric tests, particularly for ordinal scoring systems . For paired samples (e.g., normal vs. diseased tissue from the same patient), consider Wilcoxon signed-rank test or Friedman's test for multiple comparisons .

What emerging applications of ISM2 antibodies show promise for reproductive biology research?

Several emerging applications of ISM2 antibodies present exciting opportunities for reproductive biology research:

• Biomarker Development: Given the observed decrease of ISM2 in preeclampsia, longitudinal studies could evaluate its potential as an early predictive biomarker. This would require careful standardization of collection protocols and establishment of reference ranges across gestational ages .

• Functional Studies: Combining antibody-based detection with functional assays (e.g., angiogenesis assays, cell migration, invasion assays) could elucidate ISM2's precise role in placental development and pathology.

• Single-Cell Analysis: Application of ISM2 antibodies in single-cell protein profiling techniques could reveal cell-specific expression patterns within the heterogeneous placental tissue, potentially identifying specific cellular sources of ISM2 and their alteration in pathological conditions.

• Therapeutic Target Evaluation: The potential angiogenic function of ISM2 suggests it could be investigated as a therapeutic target. Neutralizing antibodies against ISM2 could be tested in appropriate models to evaluate effects on pathological angiogenesis.

• Multi-omics Integration: Combining antibody-based protein detection with genomic, transcriptomic, and metabolomic data could provide comprehensive insights into ISM2 regulation and function in reproductive processes.

How might ISM2 antibodies contribute to understanding the molecular mechanisms of preeclampsia?

ISM2 antibodies offer significant potential for elucidating preeclampsia mechanisms:

• Temporal Expression Patterns: Using ISM2 antibodies to track expression changes throughout normal pregnancy and in preeclampsia development could identify critical timepoints when ISM2 dysregulation begins .

• Signaling Pathway Analysis: Combining ISM2 detection with phospho-specific antibodies against downstream signaling molecules could map the signaling networks influenced by ISM2 in placental tissue.

• Co-localization Studies: Dual immunofluorescence staining with ISM2 antibodies and markers of specific placental cell types (trophoblasts, endothelial cells) could identify the cellular sources and targets of ISM2 action.

• Functional Blocking Studies: In appropriate ex vivo models (such as placental explants), blocking antibodies against ISM2 could help determine whether reduced ISM2 is causative or consequential in preeclampsia pathophysiology.

• Comparative Studies: Systematic analysis of ISM2 expression in different hypertensive disorders of pregnancy (preeclampsia, gestational hypertension, chronic hypertension) could clarify whether ISM2 reduction is specific to preeclampsia or a general feature of pregnancy-related hypertensive conditions .

By implementing these advanced approaches, researchers can leverage ISM2 antibodies to gain deeper insights into the complex pathophysiology of preeclampsia and potentially identify new therapeutic targets.